A Phase 3 interventional study of somatropin and leuprorelin in Idiopathic Short Stature (ISS), sponsored by Eli Lilly and Company. Completed at 19 sites in 2 countries. Open to participants aged 8 Years to 171 Months. Per ClinicalTrials.gov, last updated 2019-09-30.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The present randomized trial was initially intended to study the benefits of a combined treatment with growth hormone (GH) and a gonadotropin-releasing hormone (GnRH) agonist for pubertal children with idiopathic short stature. However, treatments were stopped in January 2012 at the request of the French drug agency. Therefore, a protocol amendment divided the study in two study periods.
Study Period 1 involved combined treatment with somatropin and leuprorelin or treatment with somatropin alone. Participants from France who participated in this Period 1 of the study were asked to participate in a long term safety follow up defined as a Period 2 of the study. Participants from the Netherlands were offered participation in Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS, clinicaltrials.gov Identifier: NCT01088412) for long term safety follow up independent of this study.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: somatropin · Drug: leuprorelin
Drug: somatropin
0.05 mg/kg/day
Also known as: LY137998, Humatrope
11.25 mg/3 months
Number of Participants With One or More Drug-related Adverse Events
A drug-related AE was an AE that occurred postdose or was present predose and became more severe postdose and was considered to be related to study treatment. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Baseline through End of Study (up to 9 years)
Adult Height Standard Deviation Score (SDS)
The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
Time frame: Baseline through End of Study (up to 9 years)
Height Velocity
Height velocity is the difference between 2 height measurements, divided by years elapsed between measurements.
Time frame: Baseline through End of Study (up to 9 years)
Height SDS
SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
Time frame: Baseline through End of Study (up to 9 years)
Difference Between Adult Height SDS and Target Height SDS
This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of target height \[calculated as (mother's height (SDS) + father's height (SDS))/2\] for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
Time frame: Baseline through End of Study (up to 9 years)
Difference Between Adult Height SDS and Baseline Predicted Height SDS
This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of baseline predicted height \[calculated using the Bayley-Pinneau method based on height and bone age\] for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
Time frame: Baseline through End up Study (up to 9 years)
Difference Between Adult Height SDS and Baseline Height SDS
This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of baseline height for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
Time frame: Baseline through End up Study (up to 9 years)
Percentage of Children With Normal Adult Height SDS
Percentage of children with normal adult height SDS (greater than -2 SDS and less than +2 SDS)
Time frame: Baseline through End of Study (up to 9 years)
Bone Age
Bone age measured using the X-Ray of left hand and wrist.
Time frame: Baseline through End of Study (up to 9 years)
| Milestone | Somatropin and Leuprorelin: Experimental Arm 1 | Somatropin: Experimental Arm 2 |
|---|---|---|
| Started | 46 | 45 |
| Received at least one dose of study drug | 45 | 43 |
| Completed | 1 | 1 |
| Not completed | 45 | 44 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Parent/caregiver decision | 1 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Sponsor decision | 34 | 32 |
| Withdrew: Protocol entry criterion not met | 0 | 1 |
| Withdrew: Other | 2 | 6 |
| Milestone | Somatropin and Leuprorelin: Experimental Arm 1 | Somatropin: Experimental Arm 2 |
|---|---|---|
| Started | 20 | 19 |
| Completed | 19 | 17 |
| Not completed | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
A drug-related AE was an AE that occurred postdose or was present predose and became more severe postdose and was considered to be related to study treatment. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
| participants | Somatropin and Leuprorelin | Somatropin |
|---|---|---|
| Study Period 1 (n=46, 45) | 42 | 38 |
| Study Period 2 (n=20, 19) | 11 | 9 |
The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
| standard deviation score | Somatropin and Leuprorelin | Somatropin |
|---|---|---|
| Adult Height Standard Deviation Score (SDS) | -1.8 ± 0.53 | -1.9 ± 0.77 |
Height velocity is the difference between 2 height measurements, divided by years elapsed between measurements.
| centimeter per year | Somatropin and Leuprorelin | Somatropin |
|---|---|---|
| Randomization (n=45, 43) | 7.8 ± 6.92 | 7.4 ± 6.03 |
| Month 3 (n=45, 43) | 9.9 ± 3.94 | 10.6 ± 3.53 |
| Month 6 (n=45, 42) | 8.1 ± 2.31 | 9.7 ± 2.80 |
| Month 12 (n=44, 42) | 7.0 ± 1.64 | 8.8 ± 2.33 |
| Month 18 (n=42, 42) | 6.6 ± 1.68 | 8.4 ± 2.64 |
| Month 24 (n=37, 41) | 4.9 ± 1.33 | 7.8 ± 3.36 |
| Month 30 (n=25, 25) | 6.2 ± 2.09 | 5.8 ± 2.93 |
| Month 36 (n=18, 19) | 6.6 ± 3.25 | 3.5 ± 2.71 |
| Month 42 (n=13, 14) | 5.7 ± 1.94 | 3.7 ± 2.17 |
| Month 48 (n=7, 8) | 5.4 ± 2.27 | 2.9 ± 2.73 |
| Month 54 (n=1, 1) | 6.3 ± 0 | 7.1 ± 0 |
| Safety follow up 6 months (n=16, 9) | 4.6 ± 2.08 | 4.5 ± 2.45 |
| Safety follow up 12 months(n=15, 8) | 2.9 ± 2.37 | 2.3 ± 1.43 |
| Safety follow up 18 months (n=12, 4) | 3.3 ± 1.69 | 1.2 ± 1.20 |
| Safety follow up 24 months (n=9, 1) | 2.0 ± 1.32 | 2.5 ± 0 |
| Safety follow up 36 months (n=5, 0) | 1.3 ± 0.53 | 0 ± 0 |
| Safety follow up 42 months (n=2, 0) | 2.1 ± 2.45 | 0 ± 0 |
| Safety follow up 12 months (final height)(n=18,14) | 0.5 ± 0.86 | 0.8 ± 1.59 |
| Safety follow up 24 months (final height) (n=7,10) | 0.3 ± 0.77 | 0.3 ± 0.97 |
| Safety follow up 36 months (final height) (n=3,7) | 0.9 ± 0.78 | 0.3 ± 0.60 |
SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
| standard deviation score | Somatropin and Leuprorelin | Somatropin |
|---|---|---|
| Randomization (n=45, 43) | -2.5 ± 0.45 | -2.5 ± 0.46 |
| Month 3 (n=45, 43) | -2.4 ± 0.42 | -2.4 ± 0.47 |
| Month 6 (n=45, 42) | -2.3 ± 0.48 | -2.2 ± 0.52 |
| Month 12 (n=44, 42) | -2.2 ± 0.50 | -2.0 ± 0.57 |
| Month 18 (n=42, 42) | -2.2 ± 0.53 | -1.9 ± 0.63 |
| Month 24 (n=37, 41) | -2.3 ± 0.58 | -1.8 ± 0.67 |
| Month 30 (n=25, 25) | -2.2 ± 0.63 | -2.0 ± 0.58 |
| Month 36 (n=18, 19) | -2.0 ± 0.65 | -2.0 ± 0.68 |
| Month 42 (n=13, 14) | -1.8 ± 0.68 | -1.9 ± 0.66 |
| Month 48 (n=7, 8) | -1.6 ± 0.52 | -1.9 ± 0.65 |
| Month 54 (n=1, 1) | -1.0 ± 0 | -1.7 ± 0 |
| Safety follow up 6 months (n=16, 9) | -2.1 ± 0.65 | -1.7 ± 0.77 |
| Safety follow up 12 months(n=15, 8) | -1.9 ± 0.55 | -1.7 ± 0.77 |
| Safety follow up 18 months (n=12, 4) | -1.9 ± 0.63 | -1.9 ± 0.78 |
| Safety follow up 24 months (n=9, 1) | -1.9 ± 0.46 | -1.2 ± 0 |
| Safety follow up 36 months (n=5, 0) | -1.9 ± 0.67 | 0 ± 0 |
| Safety follow up 42 months (n=2, 0) | -2.4 ± 0.18 | 0 ± 0 |
| Safety follow up 12 months (final height)(n=18,14) | -1.9 ± 0.46 | -1.8 ± 0.71 |
| Safety follow up 24 months (final height) (n=7,10) | -1.6 ± 0.56 | -2.0 ± 0.79 |
| Safety follow up 36 months (final height) (n=3,7) | -1.2 ± 0.90 | -2.2 ± 0.94 |
This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of target height \[calculated as (mother's height (SDS) + father's height (SDS))/2\] for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
| standard deviation score | Somatropin and Leuprorelin | Somatropin |
|---|---|---|
| Difference Between Adult Height SDS and Target Height SDS | -0.6 ± 0.89 | -1.2 ± 0.80 |
This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of baseline predicted height \[calculated using the Bayley-Pinneau method based on height and bone age\] for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
| standard deviation score | Somatropin and Leuprorelin | Somatropin |
|---|---|---|
| Difference Between Adult Height SDS and Baseline Predicted Height SDS | 1.1 ± 0.96 | 1.2 ± 0.70 |
This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of baseline height for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.
| standard deviation score | Somatropin and Leuprorelin | Somatropin |
|---|---|---|
| Difference Between Adult Height SDS and Baseline Height SDS | 0.6 ± 0.59 | 0.6 ± 0.67 |
Percentage of children with normal adult height SDS (greater than -2 SDS and less than +2 SDS)
| percentage of participants | Somatropin and Leuprorelin | Somatropin |
|---|---|---|
| Percentage of Children With Normal Adult Height SDS | 26.7 | 25.6 |
Bone age measured using the X-Ray of left hand and wrist.
| years | Somatropin and Leuprorelin | Somatropin |
|---|---|---|
| Randomization (n=45, 43) | 10.8 ± 1.58 | 11.0 ± 1.45 |
| Month 12 (n=40, 41) | 11.7 ± 1.59 | 12.1 ± 1.12 |
| Month 24 (n=34, 37) | 12.4 ± 1.32 | 13.4 ± 1.09 |
| Month 36 (n=18, 18) | 13.3 ± 1.49 | 14.5 ± 1.64 |
| Month 48 (n=7, 8) | 14.8 ± 1.33 | 15.4 ± 1.27 |
| Safety follow up 6 months (n=16, 7) | 14.1 ± 1.11 | 14.9 ± 0.81 |
| Safety follow up 18 months (n=12, 3) | 15.2 ± 1.25 | 17.0 ± 1.00 |
| Safety follow up 36 months (n=5, 0) | 15.7 ± 1.04 | 0 ± 0 |
| Safety follow up 12 months (final height)(n=18,14) | 19.6 ± 14.53 | 16.3 ± 1.27 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Somatropin and Leuprorelin | — | 12/46 (26.1%) | 41/46 (89.1%) |
| Somatropin | — | 7/45 (15.6%) | 36/45 (80%) |
| Event | Somatropin and Leuprorelin | Somatropin |
|---|---|---|
| AppendicitisInfections and infestations | 2/46 | 2/45 |
| Congenital genital malformationCongenital, familial and genetic disorders | 0/46 | 1/45 |
| GastroenteritisInfections and infestations | 0/46 | 1/45 |
| Viral infectionInfections and infestations | 0/46 | 1/45 |
| AgitationPsychiatric disorders | 0/46 | 1/45 |
| Intentional self-injuryPsychiatric disorders | 0/46 | 1/45 |
| Mental disorderPsychiatric disorders | 0/46 | 1/45 |
| Suicidal ideationPsychiatric disorders | 0/46 | 1/45 |
| NephrolithiasisRenal and urinary disorders | 0/46 | 1/45 |
| Thyroglossal cystCongenital, familial and genetic disorders | 1/46 | 0/45 |
| Event | Somatropin and Leuprorelin | Somatropin |
|---|---|---|
| HeadacheNervous system disorders | 21/46 | 16/45 |
| NasopharyngitisInfections and infestations | 19/46 | 8/45 |
| InfluenzaInfections and infestations | 15/46 | 9/45 |
| GastroenteritisInfections and infestations | 11/46 | 6/45 |
| Injection site painGeneral disorders | 8/46 | 0/45 |
| Abdominal painGastrointestinal disorders | 4/46 | 7/45 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/46 | 4/45 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/46 | 6/45 |
| TonsillitisInfections and infestations | 6/46 | 5/45 |
| PyrexiaGeneral disorders | 4/46 | 5/45 |
The full analysis set (FAS) includes all data from all randomized patients receiving at least one dose of the study drug according to the treatment to which the patients were assigned and with at least one follow-up visit.
| Age, Continuous(years) | Somatropin and Leuprorelin | Somatropin | Total |
|---|---|---|---|
| Mean | 12.1 ± 1.41 | 12.1 ± 1.33 | 12.1 ± 1.36 |
| Sex: Female, Male(Participants) | Somatropin and Leuprorelin | Somatropin | Total |
|---|---|---|---|
| Female | 26 | 20 | 46 |
| Male | 19 | 23 | 42 |
| Race (NIH/OMB)(Participants) | Somatropin and Leuprorelin | Somatropin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 38 | 40 | 78 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(participants) | Somatropin and Leuprorelin | Somatropin | Total |
|---|---|---|---|
| Netherlands | 6 | 5 | 11 |
| France | 39 | 38 | 77 |
| Standing Height SDS(Standard Deviation Score) | Somatropin and Leuprorelin | Somatropin | Total |
|---|---|---|---|
| Mean | -2.5 ± 0.45 | -2.5 ± 0.46 | -2.5 ± .045 |
| Standing Height(centimeters) | Somatropin and Leuprorelin | Somatropin | Total |
|---|---|---|---|
| Mean | 131.6 ± 6.72 | 131.6 ± 5.78 | 131.6 ± 6.24 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
The record gives a start of Jun 2006, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone